SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT

Cyklokapron 500mg Solution for Injection

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 5 mL ampoule contains 500 mg tranexamic acid.

For the full list of excipients, see section 6.1.

3 PHARMACEUTICAL FORM

Solution for intravenous injection.

Clear, colourless solution with pH 6.5-8.0.

4 CLINICAL PARTICULARS

4.1 Therapeutic indications
Prevention and treatment of haemorrhages due to general or local fibrinolysis in adults and children from one year.
Specific indications include:
- Haemorrhage caused by general or local fibrinolysis such as:
  - Menorrhagia and metrorrhagia,
  - Gastrointestinal bleeding,
  - Haemorrhagic urinary disorders, further to prostate surgery or surgical procedures affecting the urinary tract,
- Ear Nose Throat surgery (adenoidectomy, tonsillectomy, dental extractions),
- Gynaecological surgery or disorders of obstetric origin,
- Thoracic and abdominal surgery and other major surgical intervention such as cardiovascular surgery,
- Management of haemorrhage due to the administration of a fibrinolytic agent.

4.2 Posology and method of administration

Posology
Adults

Unless otherwise prescribed, the following doses are recommended:

1. Standard treatment of local fibrinolysis:
   0.5 g (1 ampoule of 5 mL) to 1 g (1 ampoule of 10 mL or 2 ampoules of 5 mL)
   tranexamic acid by slow intravenous injection (= 1 mL/minute) two to three times
daily

2. Standard treatment of general fibrinolysis:
   1 g (1 ampoule of 10 mL or 2 ampoules of 5 mL) tranexamic acid by slow
   intravenous injection (= 1 mL/minute) every 6 to 8 hours, equivalent to 15 mg/kg BW

Renal impairment

In renal insufficiency leading to a risk of accumulation, the use of tranexamic acid is
contraindicated in patients with severe renal impairment (see section 4.3). For patients
with mild to moderate renal impairment, the dosage of tranexamic acid should be
reduced according to the serum creatinine level:

<table>
<thead>
<tr>
<th>Serum creatinine μmol/l</th>
<th>Dose IV mg/kg BW</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>120 to 249</td>
<td>1.35 to 2.82</td>
<td>10 mg/kg BW</td>
</tr>
<tr>
<td>250 to 500</td>
<td>2.82 to 5.65</td>
<td>10 mg/kg BW</td>
</tr>
<tr>
<td>&gt; 500</td>
<td>&gt; 5.65</td>
<td>5 mg/kg BW</td>
</tr>
</tbody>
</table>

Hepatic impairment

No dose adjustment is required in patients with hepatic impairment.

Paediatric Population

In children from 1 year, for current approved indications as described in section 4.1,
the dosage is in the region of 20 mg/kg/day. However, data on efficacy, posology and
safety for these indications are limited.
The efficacy, posology and safety of tranexamic acid in children undergoing cardiac
surgery have not been fully established. Currently available data are limited and are
described in section 5.1.

Elderly

No reduction in dosage is necessary unless there is evidence of renal failure.

Method of administration

The administration is strictly limited to slow intravenous injection (see section 6.6).

4.3 Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section
6.1.
Acute venous or arterial thrombosis (see section 4.4)
Fibrinolytic conditions following consumption coagulopathy except in those with
predominant activation of the fibrinolytic system with acute severe bleeding (see
section 4.4)
Severe renal impairment (risk of accumulation)
History of convulsions
Intrathecal and intraventricular injection, intracerebral application (risk of cerebral
oedema and convulsions)
4.4 Special warnings and precautions for use

The indications and method of administration indicated above should be followed strictly:

- Intravenous injections should be given very slowly.
- Tranexamic acid should not be administered by the intramuscular route.

Convulsions

Cases of convulsions have been reported in association with tranexamic acid treatment. In coronary artery bypass graft (CABG) surgery, most of these cases were reported following intravenous (i.v.) injection of tranexamic acid in high doses. With the use of the recommended lower doses of tranexamic acid, the incidence of post-operative seizures was the same as that in untreated patients.

Visual disturbances

Attention should be paid to possible visual disturbances including visual impairment, vision blurred, impaired colour vision and if necessary the treatment should be discontinued. With continuous long-term use of tranexamic acid solution for injection, regular ophthalmologic examinations (eye examinations including visual acuity, colour vision, fundus, visual field etc.) are indicated. With pathological ophthalmic changes, particularly with diseases of the retina, the physician must decide after consulting a specialist on the necessity for the long-term use of tranexamic acid solution for injection in each individual case.

Haematuria

In case of haematuria from the upper urinary tract, there is a risk for urethral obstruction.

Thromboembolic events

Before use of tranexamic acid, risk factors of thromboembolic disease should be considered. In patients with a history of thromboembolic diseases or in those with increased incidence of thromboembolic events in their family history (patients with a high risk of thrombophilia), Tranexamic acid solution for injection should only be administered if there is a strong medical indication after consulting a physician experienced in hemostaseology and under strict medical supervision (see section 4.3). Tranexamic acid should be administered with care in patients receiving oral contraceptives because of the increased risk of thrombosis (see section 4.5).

Disseminated intravascular coagulation

Patients with disseminated intravascular coagulation (DIC) should in most cases not be treated with tranexamic acid (see section 4.3). If tranexamic acid is given it must be restricted to those in whom there is predominant activation of the fibrinolytic system with acute severe bleeding. Characteristically, the haematological profile approximates to the following: reduced euglobulin clot lysis time; prolonged prothrombin time; reduced plasma levels of fibrinogen, factors V and VIII, plasminogen fibrinolysin and alpha-2 macroglobulin; normal plasma levels of P and P complex; i.e. factors II (prothrombin), VIII and X; increased plasma levels of fibrinogen degradation products; a normal platelet count. The foregoing presumes
that the underlying disease state does not of itself modify the various elements in this profile. In such acute cases a single dose of 1 g tranexamic acid is frequently sufficient to control bleeding. Administration of tranexamic acid in DIC should be considered only when appropriate haematological laboratory facilities and expertise are available.

4.5. **Interaction with other medicinal products and other forms of interaction**

No interaction studies have been performed. Simultaneous treatment with anticoagulants must take place under the strict supervision of a physician experienced in this field. Medicinal products that act on haemostasis should be given with caution to patients treated with tranexamic acid. There is a theoretical risk of increased thrombus-formation potential, such as with oestrogens. Alternatively, the antifibrinolytic action of the drug may be antagonised with thrombolytic drugs.

4.6 **Fertility, pregnancy and lactation**

Women of childbearing potential have to use effective contraception during treatment.

**Pregnancy**

There are no or limited amount of data from the use of tranexamic acid in pregnant women. As a result, although studies in animals do not indicate teratogenic effects, as precaution for use, tranexamic acid is not recommended during the first trimester of pregnancy. Limited clinical data of the use of tranexamic acid in different clinical haemorrhagic settings during the second and third trimesters did not identify deleterious effect for the foetus. Tranexamic acid should be used throughout pregnancy only if the expected benefit justifies the potential risk.

**Breast-feeding**

Tranexamic acid is excreted in human milk. Therefore, breast-feeding is not recommended.

**Fertility**

There are no clinical data on the effects of tranexamic acid on fertility.

4.7. **Effects on ability to drive and use machines**

No studies have been performed on the ability to drive and use machines.

4.8 **Undesirable effects**
The ADRs reported from clinical studies and post-marketing experience are listed below according to system organ class.

**Tabulated list of adverse reactions**

Adverse reactions reported are presented in table below. Adverse reactions are listed according to MedDRA primary system organ class. Within each system organ class, adverse reactions are ranked by frequency. Within each frequency grouping, adverse reactions are presented in the order of decreasing seriousness.

<table>
<thead>
<tr>
<th>System organ class</th>
<th>Common ≥ 1/100 to &lt; 1/10</th>
<th>Uncommon ≥ 1/1,000 to &lt; 1/100</th>
<th>Frequency not known (cannot be estimated from the available data)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune system disorders</td>
<td></td>
<td></td>
<td>- Hypersensitivity reactions including anaphylaxis</td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
<td>- Convulsions particularly in case of misuse (refer to sections 4.3 and 4.4)</td>
</tr>
<tr>
<td>Eye disorders</td>
<td></td>
<td></td>
<td>- Visual disturbances including impaired colour vision</td>
</tr>
<tr>
<td>Vascular disorders</td>
<td></td>
<td></td>
<td>- Malaise with hypotension, with or without loss of consciousness (generally following a too fast intravenous injection, exceptionally after oral administration) - Arterial or venous thrombosis at any sites</td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>- Diarrhoea</td>
<td>- Vomiting - Nausea</td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td></td>
<td></td>
<td>- Dermatitis allergic</td>
</tr>
</tbody>
</table>

**Reporting of suspected adverse reactions**

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard).

**4.9. Overdose**

No case of overdose has been reported. Signs and symptoms may include dizziness, headache, hypotension, and convulsions. It has been shown that convulsions tend to occur at higher frequency with increasing dose. Management of overdose should be supportive.
5. PHARMACOLOGICAL PROPERTIES

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Antihaemorrhagics, Antifibrinolytics, Aminoacids
ATC code: B02AA02
Tranexamic acid exerts an anti haemorrhagic activity by inhibiting the fibrinolytic properties of plasmin.
A complex involving tranexamic acid, plasminogen is constituted; the tranexamic acid being linked to plasminogen when transformed into plasmin.
The activity of the tranexamic acid-plasmin complex on the activity on fibrin is lower than the activity of free plasmin alone.
In vitro studies showed that high tranexamic dosages decreased the activity of complement.

Paediatric population
In children over one year old
Literature review identified 12 efficacy studies in paediatric cardiac surgery which have included 1073 children, 631 having received tranexamic acid. Most of them were controlled versus placebo. Studied population was heterogenic in terms of age, surgery types, dosing schedules. Study results with tranexamic acid suggest reduced blood loss and reduced blood product requirements in paediatric cardiac surgery under cardiopulmonary bypass (CPB) where there is a high risk of haemorrhage, especially in cyanotic patients or patients undergoing repeat surgery. The most adapted dosing schedule appeared to be:
- first bolus of 10 mg/kg after induction of anaesthesia and prior to skin incision,
- continuous infusion of 10 mg/kg/h or injection into the CPB pump prime at a dose adapted on the CPB procedure, either according to a patient weight with a dose of 10 mg/kg dose, either according to CPB pump prime volume, last injection of 10 mg/kg at the end of CPB.
While studied in very few patients, the limited data suggest that continuous infusion is preferable, since it would maintain therapeutic plasma concentration throughout surgery.
No specific dose-effect study or PK study has been conducted in children.

5.2 Pharmacokinetic properties

Absorption
Peak plasma concentrations of tranexamic acid are obtained rapidly after a short intravenous infusion after which plasma concentrations decline in a multi-exponential manner.

Distribution
The plasma protein binding of tranexamic acid is about 3% at therapeutic plasma levels and seems to be fully accounted for by its binding to plasminogen. Tranexamic acid does not bind to serum albumin. The initial volume of distribution is about 9 to 12 litres.
Tranexamic acid passes through the placenta. Following administration of an intravenous injection of 10 mg/kg to 12 pregnant women, the concentration of tranexamic acid in serum ranged 10-53 μg/mL while that in cord blood ranged 4-31 μg/mL. Tranexamic acid diffuses rapidly into joint fluid and the synovial membrane. Following administration of an intravenous injection of 10 mg/kg to 17 patients undergoing knee surgery, concentrations in the joint fluids were similar to those seen in corresponding serum samples. The concentration of tranexamic acid in a
number of other tissues is a fraction of that observed in the blood (breast milk, one hundredth; cerebrospinal fluid, one tenth; aqueous humor, one tenth). Tranexamic acid has been detected in semen where it inhibits fibrinolytic activity but does not influence sperm migration.

**Elimination**
It is excreted mainly in the urine as unchanged drug. Urinary excretion via glomerular filtration is the main route of elimination. Renal clearance is equal to plasma clearance (110 to 116 mL/min). Excretion of tranexamic acid is about 90% within the first 24 hours after intravenous administration of 10 mg/kg body weight. Elimination half-life of tranexamic acid is approximately 3 hours.

**Special populations**
Plasma concentrations increase in patients with renal failure.
No specific PK study has been conducted in children.

### 5.3 Preclinical safety data

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. Epileptogenic activity has been observed in animals with intrathecal use of tranexamic acid.

### 6 PHARMACEUTICAL PARTICULARS

#### 6.1 List of excipients

Water for injections

#### 6.2 Incompatibilities

This medicinal product should not mixed with blood for transfusion or with solutions containing penicillin.

#### 6.3 Shelf life

3 years

After first opening: the solution for injection is for single use only. Unused solution for injection must be discarded.
Chemical and physical in-use stability has been demonstrated for 24 hours at 25°C.

From a microbiological point of view, the product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user.
6.4 Special precautions for storage

Do not freeze.
For storage conditions after first opening of the medicinal product, see section 6.3.

6.5 Nature and contents of container

Packs with 5, 6 or 10 Type I glass 5 mL ampoules in an outer carton, each ampoule containing 500 mg tranexamic acid.

Packs with 10 x 1 Type I glass 5 mL ampoules in an outer carton, each ampoule containing 500 mg tranexamic acid.

Not all pack sizes may be marketed.

6.6 Special precautions for disposal and other handling

Cyklokapron for injection may be mixed with most solutions for infusion such as electrolyte solutions, carbohydrate solutions, amino acid solutions and dextran solutions. Heparin may be added to Cyklokapron injection.

Cyklokapron for injection is for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.

7. MARKETING AUTHORISATION HOLDER

Pfizer Limited
Ramsgate Road
Sandwich
CT13 9NJ
UK

8. MARKETING AUTHORISATION NUMBER(S)

PL 00057/0952

9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORITY

9th February 1987

10 DATE OF REVISION OF THE TEXT